RaQualia Pharma Inc.
4579.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥14,038,600 | ¥12,561,849 | ¥8,036,512 | ¥8,320,250 |
| - Cash | ¥3,543,230 | ¥3,422,513 | ¥2,764,423 | ¥3,141,929 |
| + Debt | ¥3,049,436 | ¥3,196,859 | ¥3,344,484 | ¥3,521,991 |
| Enterprise Value | ¥13,544,806 | ¥12,336,195 | ¥8,616,573 | ¥8,700,312 |
| Revenue | ¥775,053 | ¥570,563 | ¥965,409 | ¥738,137 |
| % Growth | 35.8% | -40.9% | 30.8% | – |
| Gross Profit | ¥548,502 | ¥335,277 | ¥672,586 | ¥509,228 |
| % Margin | 70.8% | 58.8% | 69.7% | 69% |
| EBITDA | ¥856 | -¥185,035 | ¥162,046 | ¥4,896 |
| % Margin | 0.1% | -32.4% | 16.8% | 0.7% |
| Net Income | -¥214,237 | -¥349,532 | -¥5,215 | -¥155,138 |
| % Margin | -27.6% | -61.3% | -0.5% | -21% |
| EPS Diluted | -8.76 | -15.25 | -0.24 | -7.16 |
| % Growth | 42.6% | -6,254.2% | 96.6% | – |
| Operating Cash Flow | ¥70,042 | ¥57,055 | -¥301,595 | -¥48,358 |
| Capital Expenditures | -¥14,568 | -¥37,537 | -¥11,444 | ¥210 |
| Free Cash Flow | ¥55,474 | ¥19,518 | -¥313,039 | -¥48,148 |